Lantheus (LNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading remains neutral on the stock and has a $114.00 price target.
Justin Walsh has given his Buy rating to Lantheus based on the company’s proactive steps to solidify and expand its standing as a prominent player in the radiopharmaceutical industry while also mitigating investment risks in the medium to long term. Lantheus has shown a commitment to growing its PSMA-targeted PET imaging franchise, albeit at a slower pace post-initial launch, and is investing in a diverse pipeline with various radioisotopes, which offers multiple medical applications and commercial opportunities. Additionally, Walsh appreciates the company’s prudent approach to business development, which preserves capital and maintains strategic flexibility.
The analyst also highlights the importance of a diversified pipeline in the radiopharmaceutical space, where the unique properties of different isotopes can be tailored for specific clinical applications. This versatility in isotope selection not only allows for medical innovation but also introduces redundancies that can reduce commercial risk. Walsh believes that the market has undervalued Lantheus due to premature competitive concerns regarding one of its assets, while overlooking the company’s consistent and effective commercial execution and the broader potential of its diverse portfolio.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lantheus (LNTH) Company Description:
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More on LNTH:
- Perspective Therapeutics enters strategic agreements with Lantheus
- Lantheus expands radiopharmaceutical oncology pipeline via agreements
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
- Lantheus Reports Preliminary Fiscal Year 2023 Revenue
- Lantheus sees 2023 revenue $1.295B-$1.297B, consensus $1.27B
